MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Companies

Intas BioPharmaceuticals

Intas BioPharmaceuticals
Research driven, human biotherapeutics company focused on rDNA products offering out-licensing of biogeneric bulk-API and finished formulations, contract research and contract manufacturing services.

The company in detail

Profile

 

IBPL is an integrated biopharmaceutical company with in house facility for development, manufacturing of bulk and finished formulation. The facility is GMP certified from Europe, South-Africa, GCC to name a few. With Peg GCSF, GCSF, EPO and IFN commercialized, business alliances in 78 countries and seven more biosimilar molecules under development (including Mabs and fusion proteins), IBPL is on the path to become Global Biopharmaceutical Company. Knowledge, Quality, Speed and innovative business models are driving force of IBPL. It is scouting for business partners for its Products. IBPL provides CRAMS and clinical trial services in biologics with its sister concerns.

 

Intas Biopharmaceuticals (IBPL) made a strategic entry into the biotechnology arena in 2001 via the establishment of Indus Biotherapeutics Ltd.; a dedicated biotech research company, in Ahmedabad INDIA.

Indus focuses on the development of recombinant protein-based biotherapeutics for human use. The focus is on developing commercial-scale technology in a timely and cost effective way. Our expertise lies in recombinant strain development, process and product development, development of analytical methods, bio-chemical immunological analysis, process validation and scale-up.

 

Partnering strategy/interests

We would like to tie up with a company who has strong regulatory, manufacturing and marketing capabilities. We are open to consider early stage tie ups for some of our ealry stage development biosimilars.

Services

IBPL offers GMP manufacturing services to fulfill client's pre-clinical, clinical and commercial requirements in the space of recombinant proteins & monoclonal antibodies. More
At IBPL, we offer extensive research services in bioprocess development based on microbial and mammalian technology platforms, analytical method development and method validation. More

R&D

To view this information, you must subscribe to PL Intelligence.

Press Releases

(2nd Nov 2009) Intas Biopharmaceuticals Limited (IBPL) and European pharmaceutical major Kwizda Pharma GmbH has jointly completed Phase I clinical trial study of NEUKINE®, biosimilar form of recombinant GCSF. More
(2nd Nov 2009) Ahmedabad-based Intas Biopharmaceuticals today said it has signed an MoU with the Gujarat government for setting up a Rs 160 crore facility dedicated to Monoclonal Antibodies (MAbs) at Sanand in Gujarat. More
(1st Jun 2005) The scope of the agreement covers process development and long term supply of a novel recombinant protein for clinical and commercial use. More
More press releases

Clients in focus...

Get the Flash Player to see this rotator.

Partnering discussion free of charge
BioTrinity
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us